Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era

Main Article Content

Valeria Internò
Roberta Rudà https://orcid.org/0000-0001-9134-1537
Maria Chiara Sergi https://orcid.org/0000-0002-3093-6841
Riccardo Soffietti https://orcid.org/0000-0002-9204-7038
Camillo Porta https://orcid.org/0000-0003-2412-1563

Keywords

Glioblastoma Multiforme, Hypofractioned radiotherapy, Covid-19, In-hospital contagion, Multimodal therapy

Abstract

COVID-19 pandemic revolutionized the way in which cancer patients are treated worldwide. Regarding neuro-oncological patients, usually considered frail and with lower life-expectancy in respect to other oncological patients, the international scientific community had to urgently reorganize the treatment approach in order to minimize the risk of in-hospital contagious. For GBM patients, adjuvant treatments have been evaluated with even much more attention with regard to the expected efficacy. As a consequence, an hypofractioned radiotherapy regimen has been preferred in order to reduce the daily hospital accesses and, especially in pMGMT unmethylated patients, chemotherapy with Temozolomide was avoided. Here, we made a comprehensive evaluation of the neurooncological community suggestions regarding GBM treatment in the pre-vaccine era of COVID-19 pandemic.

Downloads

Download data is not yet available.
Abstract 87 | PDF Downloads 63

References

1. Peng L, Zagorac S, Stebbing J Managing patients with cancer in the COVID-19 era Eur J Cancer 2020:132:5-7
2. Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X COVID-19 in cancer patients: risk, clinical features, and management Cancer Biol Med 2020:17(3):519-527
3. Cazzato G, Foti C, Colagrande A et al Skin Manifestation of SARS-CoV-2: The Italian Experience J Clin. Med 2021:10:566
4. Delgado-López PD, Corrales-García EM Survival in glioblastoma: a review on the impact of treatment modalities Clin Transl Oncol 2016:18(11):1062-1071
5. Weinkove R, McQuilten ZK, Adler J et al Managing hematology and oncology patients during the COVID-19 pandemic: interim consensus guidance Med J Aust 2020:212(10):481-489
6. Pessina F, Navarria P, Bellu L, et al Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future Neurosurg Focus 2020:49(6):E10
7. Weller M, Preusser M How we treat patients with a brain tumour during the COVID-19 pandemic ESMO Open 2020:4(Suppl 2):e000789
8. Bernhardt D, Wick W, Weiss SE, et al Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas [published online ahead of print, 2020 May 5] Neuro Oncol 2020:22(7):928-935
9. Mrugala MM, Ostrom QT, Pressley SM et al The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment Neurooncol Adv 2021:3(1):vdab035
10. Stupp R, Mason WP, van den Bent MJ, et al Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 2005:352(10):987-996
11. Perry JR, Laperriere N, O'Callaghan CJ, et al Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma N Engl J Med 2017:376(11):1027-1037
12. Pellerino A, Bruno F, Internò V, Rudà R, Soffietti R Current clinical management of elderly patients with glioma Expert Rev Anticancer Ther 2020:20(12):1037-1048
13. Gay HA, Santiago R, Gil B, et al Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients Pract Radiat Oncol 2019:9(5):305-321
14. Hegi ME, Stupp R. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma? Neuro Oncol 2015:17(11): 1425-1427
15. Kamson DO, Grossman SA The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic JAMA Oncol 2021:7(5):675-676
16. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Lancet 2020:395(10223):473-475